News
-
-
-
COMMUNIQUÉ DE PRESSE
POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
Amgen's Repatha receives positive CHMP opinion to expand use for cardiovascular disease risk reduction in high-risk adults without prior heart attack or stroke, based on VESALIUS-CV trial results -
-
-
COMMUNIQUÉ DE PRESSE
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
The European Commission has approved Amgen's IMDYLLTRA as a monotherapy for treating extensive-stage small cell lung cancer with a significant survival benefit over chemotherapy -
-
-
